Heavy ion beam treatment composition
By combining the chemokine eMIP and alarm hormone HSP70 in the heavy ion beam therapy composition, various lymphocytes and NK cells are activated, solving the treatment challenge of micrometastases, achieving significant inhibition of solid tumors and prevention of distant metastasis, and enhancing the remote effect of the immune system.
Patent Information
- Application Number
- CN202411205025.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies are difficult to effectively treat micrometastases, especially in heavy ion beam therapy, which cannot effectively prevent distant metastasis of cancer cells, and traditional methods damage normal tissues and have limited immune activation effects.
The heavy ion beam therapy composition, which includes the combined use of chemokine eMIP and alarm molecule HSP70, enhances the body's anti-tumor immune response by activating a variety of lymphocytes and NK cells.
It significantly inhibits the proliferation of solid tumors, prevents distant metastasis of cancer cells, improves treatment efficacy, reduces damage to normal tissues, and enhances the remote effect of the immune system.
Smart Images

Figure CN118949012A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of cancer treatment, and in particular, relates to a heavy ion beam therapy composition, and more particularly, relates to a heavy ion beam therapy composition comprising a chemokine and an alarmin. Background Art
[0002] "Solid cancer" consists of cancers that occur on epithelial cells and non-epithelial sarcomas. It is a malignant neoplasm that continues to proliferate abnormally due to the mutation of multiple genetic genes in cells, which loses the function of controlling proliferation. Normally, biological defense mechanisms including the human immune mechanism will eliminate abnormal cells, but when cancer occurs, due to low immunogenicity, the specific immune mechanism does not work. After that, immune checkpoint proteins represented by PD-L1 are expressed, and the response of corresponding T lymphocytes (PD-1 and CTLA-4 expressing cells) is disturbed. When solid cancer reaches a certain size, cancer cells will invade adjacent organs and metastasize to other organs through blood vessels and proliferate. There are also many cases where metastases are found at the same time as "solid cancer" is diagnosed. It is believed that many undetectable micro-cancers are metastasizing before that. In order to improve the survival rate of patients, the control of metastatic cancer is a major problem that cannot be avoided clinically.
[0003] In the treatment of "solid cancer", systemic treatments such as chemotherapy are generally used at the same time as the removal of the affected part. In the typical chemotherapy used as the first choice of medicine in the past, the goal is to increase the difference in the proliferation rate of cancerous tissue and normal tissue cells. However, since it is a treatment method that affects the whole body, some normal tissue cells in the body are damaged before cancer cells. The damage to the body's defense system is particularly problematic. Many chemotherapy drugs damage white blood cells including neutrophils and lymphocytes. Therefore, since the body's defense system cannot function normally, it is impossible to rely on the incomplete tumor defense system, and a small number of remaining cancer cells continue to survive while repeatedly mutating. Recently, systemic therapy based on the development of immunology to inhibit the activity of checkpoint proteins has also begun to be widely tried, but this has shown that the integrity and activation of the body's defense system is very important. However, such immunological methods have actually been reported to cause side effects due to the suppression of the overall immune function, and the number of lymphocytes that can be recruited is limited, so the effect of single therapy relying solely on each defense system is not sufficient.
[0004] On the other hand, local treatments for solid cancers other than surgical removal, such as radiotherapy, radiofrequency ablation, and thermotherapy, are widely used. However, these treatments themselves have limitations in the treatment area due to various factors. Depending on the treatment, there are also limitations such as low-sensitivity "cancer" cells and tissues. In X-ray therapy, which is the most widely used radiotherapy, inflammation caused by reactive oxygen species generated after irradiation and recruitment of defense cells play an important role in suppressing cancer cell proliferation, and as a result, the participation of the activated immune system is important for improving prognosis. In fact, there are also reports that after local irradiation of cancer, metastatic lesions are also reduced, and cases of remote effects occur. The mechanism behind this is believed to be the result of the enhancement of the immune system after irradiation.
[0005] Since the abscopal effect produced by X-ray therapy itself actually depends on the body's defense system, attempts are currently being made to induce abscopal effects by enhancing immune responses after radiotherapy. For example, in animal experiments, it has been reported that administration of Flt3-L (Fms-related tyrosine kinase3ligand), a growth factor for dendritic cells that has an antigen-presenting function, can induce antigen-specific abscopal effects. In particular, in recent years, the understanding of the limitations of immune cell-related receptors, antibodies against PD1 and CTLA-4, and immune checkpoint inhibitors has deepened, and the focus of recent research has been on the combined use of immune activation therapy and radiotherapy. In actual clinical trials, it has also been reported that the efficiency of inducing abscopal effects has been improved by administering GM-CSF (Granulocyte-macrophage colony-stimulating factor), which has a role in promoting dendritic cell maturation, after radiotherapy.
[0006] On the other hand, electron beams used in radiotherapy are only effective on cancers on the surface of the body due to their physical properties. Also, like X-rays, their effects require inflammation and recruitment of defense cells after irradiation, so metastatic cancer is not an indication for this therapy. However, there are reports that even when electron beams are used, if a variant of the chemokine CCL3, eMIP, is used simultaneously after irradiation, it can inhibit local tumor growth and cause abscopal effects. The reason for this effect is that in addition to the activation of cancer antigen-specific T cells, nonspecific NK cells are also activated.
[0007] The effect of X-rays depends on the oxygen content in the local cancer cells, and X-rays themselves are not effective in killing cancer cells. Therefore, in both preclinical and clinical trials, methods have been tried to enhance the immune response after radiotherapy to improve the treatment effect. Recent studies have shown that lymphocytes necessary for enhancing immunity can be damaged by X-ray irradiation, which casts doubt on this tactic to fight cancer. When radiation passes through tissues, low-LET (linear energy transfer density) X-rays with low energy deposited per unit length will be indirectly affected by the local oxygen of the tumor when irradiating solid cancer. In contrast, high-LET radiation, such as heavy ion beams such as carbon ion beams, which have high local tumor efficacy, are believed to act directly on the biological molecules of the irradiated cells. In other words, high-LET radiation has a higher biological effect and a greater cell-killing effect, is not affected by oxygen, does not rely on the cell cycle of cancer cells, and the DNA damage it causes is difficult to repair. In particular, carbon ion beam therapy has a higher biological effect and excellent dose distribution characteristics in the affected area compared to traditional X-rays, even fast neutron rays and proton beams.
[0008] Therefore, in order to improve the treatment results of heavy particle beam radiotherapy, the most important issue is to develop a treatment method for micrometastatic cancer. Distant metastasis of cancer cells is formed by breaking away from the primary lesion, invading blood vessels through the surrounding interstitial tissue, adhering to the endothelial cells of the venules and capillaries of specific target organs, breaking the basement membrane and infiltrating into the organs, where they grow and continue to proliferate. The biggest problem in clinical practice is that usually when patients are diagnosed with cancer, they have already formed micrometastatic cancer that has infiltrated multiple organs.
[0009] Even with highly sensitive PET diagnosis, the detection limit is a tumor with a diameter of 5 mm. Therefore, the most important issue in heavy particle beam therapy is to develop a treatment method for micro-metastatic cancer that cannot be diagnosed by CT and PET.
[0010] This patent relates to a therapeutic composition for the above-mentioned conditions that has the effect of enhancing the defense response of the biological body. Summary of the invention
[0011] The applicant creatively discovered that unlike the previous radiotherapy combined with immunotherapy that activates a single immune cell, the present invention uses CCL3 variants to chemotaxis and activate multiple lymphocytes and NK cells to work together to enhance the body's anti-tumor immunity, thereby obtaining a higher anti-metastasis effect and ultimately achieving the purpose of treating cancer metastasis.
[0012] In view of this, in a first aspect, the present invention provides a heavy ion beam therapy composition, comprising: a first reagent combination, wherein the first reagent combination comprises a chemokine and an alarmin.
[0013] The composition of the present invention can assist heavy ion beam anti-cancer treatment, not only can significantly inhibit the proliferation of solid cancer, but also can prevent the distant metastasis of solid cancer cancer cells.
[0014] Furthermore, the concentration ratio of the chemokine to the alarmin is 2:(0.125-2); preferably, the concentration ratio of the chemokine to the alarmin is 4:1.
[0015] Furthermore, the therapeutically effective amount of the chemokine is: 1-5 μg; preferably, 2 μg.
[0016] Furthermore, the therapeutically effective amount of the alarmin is: 0.25-1.25 μg; preferably, 0.5 μg.
[0017] Furthermore, the composition also includes: a first component, which can produce a heavy ion beam.
[0018] Furthermore, the heavy ion beam is a carbon ion beam.
[0019] Further, the irradiation dose of the carbon ion beam is ≥1Gy. In some specific embodiments, the irradiation dose of the carbon ion beam can be 1Gy, 2Gy, 3Gy, 4Gy, 5Gy, 6Gy, 10Gy, 20Gy, 50Gy, 100Gy, etc. Further, the chemokine is CCL3, a variant of CCL3, a fragment of CCL3, or a derivative of CCL3.
[0020] In a specific embodiment, the chemokine has an amino acid sequence in which aspartic acid at position 27 of CCL3 is substituted by alanine.
[0021] In some specific embodiments, the chemokine has an amino acid sequence in which the first alanine of CCL3 is deleted.
[0022] In some specific embodiments, the chemokine has an amino acid sequence in which the alanine at position 1 of CCL3 is deleted and the aspartic acid at position 27 is substituted by alanine.
[0023] In a specific embodiment, the chemokine is eMIP, whose amino acid sequence (SLAADTPTACCFSYTSRQIPQNFIAAYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA), such as Figure 1 As shown in A.
[0024] In a specific embodiment, the amino acid sequence of the chemokine is Figure 1 As shown in B.
[0025] Furthermore, the alarmin is a heat shock protein.
[0026] Furthermore, the heat shock protein is HSP60, or HSP70, preferably, HSP70.
[0027] In a second aspect, the present invention provides use of the above composition for preparing a kit for treating cancer.
[0028] Furthermore, the present invention provides use of the above composition for preparing a kit for heavy ion beam therapy of cancer.
[0029] Furthermore, the cancer is a solid cancer.
[0030] Furthermore, the solid cancer is prostate cancer, head and neck tumors, liver cancer, lung cancer, intestinal cancer, bone marrow recurrence after colorectal cancer surgery, bone soft part tumors, cervical cancer, and pancreatic cancer.
[0031] In a third aspect, the present invention provides a cancer treatment kit, comprising: a first reagent combination, wherein the first reagent combination comprises a chemokine and an alarmin.
[0032] Furthermore, the concentration ratio of the chemokine to the alarmin is 2:(0.125-2); preferably, the concentration ratio of the chemokine to the alarmin is 4:1.
[0033] Furthermore, the therapeutically effective amount of the chemokine is: 1-5 μg; preferably, 2 μg.
[0034] Furthermore, the therapeutically effective amount of the alarmin is: 0.25-1.25 μg; preferably, 0.5 μg.
[0035] Furthermore, the kit also includes: a first component, which can generate a heavy ion beam.
[0036] Furthermore, the heavy ion beam is a carbon ion beam.
[0037] Further, the irradiation dose of the carbon ion beam is ≥1Gy. In some specific embodiments, the irradiation dose of the carbon ion beam can be 1Gy, 2Gy, 3Gy, 4Gy, 5Gy, 6Gy, 10Gy, 20Gy, 50Gy, 100Gy, etc. Further, the kit can also include other reagents for treating cancer.
[0038] Furthermore, the chemokine is CCL3, a variant of CCL3, a fragment of CCL3 or a derivative of CCL3.
[0039] In a specific embodiment, the chemokine has an amino acid sequence in which aspartic acid at position 27 of CCL3 is substituted by alanine.
[0040] In some specific embodiments, the chemokine has an amino acid sequence in which the first alanine of CCL3 is deleted.
[0041] In a specific embodiment, the chemokine is eMIP, whose amino acid sequence is as follows Figure 1 As shown in A.
[0042] In a specific embodiment, the amino acid sequence of the chemokine is as shown in SEQ ID NO.2.
[0043] Furthermore, the alarmin is a heat shock protein.
[0044] Furthermore, the heat shock protein is HSP60, or HSP70, preferably, HSP70.
[0045] Furthermore, the cancer is a solid cancer.
[0046] Furthermore, the solid cancer is prostate cancer, head and neck tumors, liver cancer, lung cancer, intestinal cancer, bone marrow recurrence after colorectal cancer surgery, bone soft part tumors, cervical cancer, and pancreatic cancer.
[0047] In a third aspect, the present invention provides a method for treating cancer, comprising administering the first agent combination in the heavy ion beam therapy composition of the present invention to a subject.
[0048] Further, the treatment method includes administering a heavy ion beam to the subject.
[0049] Furthermore, the heavy ion beam is a carbon ion beam.
[0050] Furthermore, the irradiation dose of the carbon ion beam is ≥1 Gy. In some specific embodiments, the irradiation dose of the carbon ion beam can be 1 Gy, 2 Gy, 3 Gy, 4 Gy, 5 Gy, 6 Gy, 10 Gy, 20 Gy, 50 Gy, 100 Gy, etc.
[0051] Further, administration of the first agent combination is by intravenous administration.
[0052] Furthermore, the administration ratio of the components of the first reagent combination is that the concentration ratio of the chemokine to the alarmin is 2:(0.125-2); preferably, the concentration ratio of the chemokine to the alarmin is 4:1.
[0053] In a specific embodiment, the administration of each component of the first agent combination is chemokine: 2 μg / day, administered for 5 consecutive days; alarmin: 0.5 μg / day, administered for 5 consecutive days.
[0054] Furthermore, the cancer is a solid cancer.
[0055] Furthermore, the solid cancer is prostate cancer, head and neck tumors, liver cancer, lung cancer, intestinal cancer, bone marrow recurrence after colorectal cancer surgery, bone soft part tumors, cervical cancer, and pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 is the protein sequence of the chemokine of the present invention, Figure 1 A is the amino acid sequence of the eMIP protein; Figure 2 B is the amino acid sequence of CCL3 protein.
[0057] Figure 2 The changes in tumor volume after administration of eMIP polypeptide after local irradiation with X-rays or carbon ion beams, Figure 2 A is a graph showing the increase in tumor volume as measured by day; Figure 2 B compares the results of each group on the 21st day of irradiation; Figure 2 C is a graph showing the changes in tumor volume over the days during treatment; Figure 2 D is the comparison of the results of each group on the 21st day of irradiation.
[0058] Figure 3 To investigate the effect of administration of two peptides, eMIP and HSP70, on the increase of tumor volume after local carbon ion beam irradiation. Figure 3 A is a graph showing the increase in tumor volume as measured by day; Figure 3 B is the comparison of the results of each group on the 21st day of irradiation; Figure 3 C is a graph showing the changes in tumor volume over the days during treatment; Figure 3 D is the comparison of the results of each group on the 21st day of irradiation.
[0059] Figure 4 The number of lung metastases is shown when two polypeptides, eMIP and HSP60, or eMIP and HSP70, were administered after local carbon ion beam irradiation.
[0060] Figure 5 The number of lung metastases after administration of different concentrations of HSP70 when two polypeptide compositions of eMIP and HSP70 were administered. DETAILED DESCRIPTION
[0061] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.
[0062] [Differences between X-rays and carbon ion beams]
[0063] In radiotherapy, X-rays (photon rays) are the most widely used for cancer treatment. They are essentially low-LET (linear energy transfer) radiation. The radiation decomposition of water in the body caused by irradiation produces hydroxyl radicals (HO·), hydrogen radicals (H·), hydrated electrons (eaq - ) or the products of hydrogen peroxide occupy the main part of the radiation effect. These active oxygen species react chemically with various biological substances with the target molecule DNA as the center, thereby causing damage to cancer cells. This reaction can only produce significant effects (oxygen effect) under the condition of high oxygen partial pressure. However, due to the inadequate development of the local vascular system of cancer cells, the supply of oxygen is limited, and the cancer cells themselves also show adaptation to proliferation under anaerobic conditions, so the therapeutic effect is not sufficient. During X-ray therapy, the organism instead responds to the cell damage caused by the generated active oxygen, and it is believed that the contribution of inducing defense cells in participating in the anti-tumor process is greater.
[0064] In contrast, in heavy particle beams, such as high-LET carbon ion beams, which are extremely effective in treating local tumors, it is generally believed that the particle beams act directly on the DNA molecules that constitute cancer cells inside the body and do not require oxygen. In X-rays, multiple fields are required from different directions to reduce the radiation dose irradiated on normal organ tissues, but in heavy ion beam therapy, multiple fields are not required, so the radiation dose irradiated on normal organs is less. In particular, carbon ion beam therapy has higher biological effects and excellent dose distribution characteristics at the affected area compared to traditional X-rays and gamma rays, and even fast neutron rays and proton beams. In other words, in heavy ion beam therapy, compared with X-rays with relatively high surface doses, the absorbed dose on the body surface is lower, and it has the characteristic of reaching the maximum dose locally at the tumor.
[0065] [Chemokines and their variants and fragments]
[0066] In the present invention, the polypeptide called eMIP is a known protein composed of 69 amino acids, which is a variant of CCL3, a chemotactic protein and chemokine present in the human body. In the amino acid sequence of CCL3, aspartic acid at position 27 is replaced by alanine, which is composed of 69 amino acids. The polypeptides in the present invention also include polypeptides having the same activity as the eMIP polypeptide, which have deletions, substitutions, additions and insertions of the amino acid sequence shown in sequence A. There is no particular limitation on the scope of the deletion in the amino acid sequence, for example, it includes fragments having more than 40 deletions but having the same amino acid sequence as the eMIP polypeptide, and having the same activity as the eMIP polypeptide.
[0067] The combination of eMIP and local electron beam therapy for tumors has significant tumor inhibitory effects, including complete remission of locally irradiated tumors, antigen-nonspecific tumor inhibitory effects in non-irradiated sites, and prolonged survival. In addition, the combination of eMIP and radiofrequency ablation has clarified that this combination therapy inhibits the recurrence of primary liver cancer. In addition, the administration of eMIP after local hyperthermia treatment of the tumor also showed anti-tumor and anti-cancer metastasis effects.
[0068] [Alarmone]
[0069] In the present invention, the polypeptide referred to as HSP70 is a heat shock protein called alarmin, which is composed of 70 kilodaltons and is induced during infection or cell damage. This molecule can activate antigen presenting cells, dendritic cells. In the present invention, the alarmin administered simultaneously with eMIP is preferably various heat shock proteins, more preferably heat shock protein HSP70. In the HSP70 of the present invention, amino acid sequence information is disclosed. The sequence information of human HSP70 is registered in GenBank as NP-002145, AAI26125, etc., and this information can be used. In the present invention, HSP70 has 1 to several amino acid deletions, substitutions, additions, and insertions in the known sequence, and also includes proteins with the same activity as the known sequence. The range of 1 to several is not particularly limited, for example, 1 to 20, preferably 1 to 10, more preferably 1 to 7, further preferably 1 to 5, particularly preferably 1 to 3, or 1 to 2. The present invention also includes polypeptides having a sequence identity of 90% or more, more preferably 95% or more, and most preferably 98% or more to a known amino acid sequence.
[0070] In the present invention, the eMIP and HSP70 shown in sequence A can be produced and purified using genetic engineering methods known to those skilled in the art. It is well known that bacteria, yeast, insect cells, animal cells, and plant cells can all use corresponding gene introduction vectors. Since these are known technologies, detailed descriptions are omitted.
[0071] The expressed polypeptide can be obtained from the culture supernatant of the host cells obtained in this step or the disrupted liquid of the expressed host cells by using a known method related to protein purification. Since these are known techniques, detailed descriptions thereof will be omitted.
[0072] The HSP70 registered in eMIP and GenBank shown in sequence A of the present invention can be prepared by a protein chemical synthesis method known to those skilled in the art. For example, the protein can be synthesized by using the Fmoc solid phase synthesis method. For example, partial peptides in the entire composition can be synthesized, and polypeptides can be synthesized by combining these partially synthesized partial peptides. The synthesized polypeptide can be purified by the above method. These are well-known techniques, so detailed descriptions are omitted.
[0073] [Dosage method]
[0074] The pharmaceutical composition of the present invention can be administered orally or parenterally. For parenterally, it can be administered by intravenous administration, intraarterial administration, local injection, abdominal cavity, thoracic cavity administration, subcutaneous injection, intramuscular administration, sublingual administration, percutaneous absorption, rectal administration and other administration methods. Specifically, it can be adjusted to various preparation forms such as injection, suspension, emulsifier, ointment, cream, tablet, powder, granule, capsule, suppository, etc. These various preparations can be made by conventional methods using commonly used excipients, extenders, adhesives, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, dissolution aids, preservatives, colorants, flavoring agents, stabilizers, etc. Since these are known technologies, detailed description is omitted.
[0075] Example 1. Changes in tumor volume after administration of eMIP polypeptide after local irradiation with X-rays or carbon ion beams
[0076] 1) Experimental methods
[0077] Mice: Female BALB / c mice were purchased from SLC, Japan, at 6 weeks of age and were used at 7 weeks of age after cis-rearing.
[0078] Drug: Recombinant eMIP polypeptide shown in sequence A
[0079] Cancer cells: Mouse colon cancer Colon26
[0080] Method 1×10 5Colon26 cells were implanted subcutaneously in the hind limb. After 9 days, when the diameter of the transplanted tumor reached about 1.0 cm, the tumor size was uniformly grouped and irradiated with 6Gy of X-ray (200kV, 14.6mA) or 3Gy and 6Gy of carbon ion beam (290MeV / u, 6cm SOBP center). From the second day, 0.2ml of eMIP (10μg / ml) was administered once a day through the tail vein for 5 consecutive days. The tumor volume of the group with only transplanted cancer cells (control), the group with only eMIP without radiation irradiation (eMIP), the group with 6Gy of X-ray (X6Gy) or 3Gy (C3Gy) and 6Gy of carbon ion beam irradiation (C6Gy), and the group with eMIP after radiation irradiation (X6Gy+eMIP, C3Gy+eMIP, C6Gy+eMIP) was deduced, and the change of tumor diameter over time after radiation treatment was measured. The tumor volume was calculated according to the following formula.
[0081] Tumor volume = long diameter of tumor × (short diameter of tumor) 2 ×0.5236
[0082] 2) Experimental results
[0083] The measurement results are as follows Figure 2 shown. Figure 2 A is a graph showing the increase in tumor volume measured over days. When eMIP was administered alone for 5 times, no change in tumor volume was observed compared to the untreated control group, but after 6Gy X-ray irradiation, inhibition of tumor volume growth was observed. Administration of eMIP after 6Gy X-ray irradiation further inhibited the increase in tumor volume. Figure 2 B compares the results of each group on day 21 after irradiation. In the group to which eMIP was administered after 6 Gy X-ray irradiation, a significant tumor suppressive effect was confirmed compared with the group not to which eMIP was administered.
[0084] Figure 2 C is a graph showing the changes in tumor volume over the days during treatment. Figure 2 D is a comparison of the results of each group on the 21st day of irradiation. Compared with the control, 3Gy carbon ion beam irradiation suppressed the increase in tumor volume, and 6Gy carbon beam irradiation further enhanced the effect of carbon ion beam and further suppressed the increase in tumor volume. However, the administration of eMIP had no effect under any dose of carbon ion beam irradiation.
[0085] Example 2: Effect of administration of two peptides, eMIP and HSP70, on tumor volume increase after local carbon ion beam irradiation
[0086] 1) Experimental methods
[0087] Mice: Female BALB / c mice were purchased from SLC, Japan, at 6 weeks of age and were used at 7 weeks of age after cis-rearing.
[0088] Drug: eMIP, HSP70 and 3 peptides of HSP60 shown in sequence A
[0089] Cancer cells: Mouse colon cancer Colon26
[0090] Method 1×10 5 Colon26 cells were implanted subcutaneously in the hind limbs. After 9 days, when the diameter of the transplanted tumor reached about 1.0 cm, the tumors were grouped according to their size and irradiated with 3Gy carbon ion beam (290MeV / u, 6cm SOBP center). From the second day, 0.2 ml of the combination of eMIP (10μg / ml) and HSP70 (2.5μg / ml) or 0.2 ml of the combination of eMIP (10μg / ml) and HSP60 (2.5μg / ml) was administered once a day through the tail vein for 5 consecutive days.
[0091] The tumor volumes of the group with only cancer cells transplanted (control), the group with eMIP and HSP70 administered without irradiation (eMIP+HSP70), the group with 3Gy carbon ion beam irradiation (C3Gy), and the group with eMIP and HSP70 administered after irradiation (C3Gy+eMIP+HSP70) were estimated, and the changes in tumor diameter over time after irradiation were measured. The tumor volume was calculated according to the following formula.
[0092] Tumor volume = long diameter of tumor × (short diameter of tumor) 2 ×0.5236
[0093] 2) Experimental results
[0094] The results of the test are as follows Figure 3 shown. Figure 3 A is a graph showing the increase in tumor volume measured by day. In the group that received 5 administrations of the mixture of eMIP and HSP70 polypeptides, no change was found in the proliferation of tumor volume compared to the untreated control group. Compared with the control, 3Gy carbon ion beam irradiation inhibited the increase in tumor volume. After 3Gy carbon ion beam irradiation, 5 administrations of the mixture of eMIP and HSP70 polypeptides further inhibited the increase in tumor volume. Figure 3 B is a comparison of the results of each group on the 21st day after irradiation. In the group to which the mixture of eMIP and HSP70 polypeptides was administered five times after 3 Gy carbon ion beam irradiation, a significant tumor suppression effect was confirmed compared with the non-administration group.
[0095] Figure 3 C is a graph showing the changes in tumor volume over the days during treatment. Figure 3D is a comparison of the results of each group on the 21st day after irradiation. In the absence of irradiation, the group that received 5 doses of the eMIP and HSP60 peptide mixture showed no change in the increase in tumor volume compared to the untreated control group. 3Gy carbon ion beam irradiation suppressed the increase in tumor volume compared to the control group. However, after 3Gy carbon ion beam irradiation, even 5 doses of the eMIP and HSP60 peptide mixture did not further suppress the increase in tumor volume.
[0096] Example 3 Number of lung metastases after administration of two polypeptides each of eMIP and HSP60, or eMIP and HSP70, after local carbon ion beam irradiation
[0097] 1) Experimental methods
[0098] Mice: Female BALB / c mice were purchased from SLC, Japan, at 6 weeks of age and were used at 7 weeks of age after cis-rearing.
[0099] Drug: eMIP, HSP60 and 3 peptides of HSP70 shown in sequence A
[0100] Cancer cells: Mouse colon cancer Colon26
[0101] Method 1×10 5 Colon26 cells were implanted subcutaneously in the hind limbs. After 9 days, when the diameter of the transplanted tumor reached about 1.0 cm, the tumors were grouped according to their size and irradiated with 3Gy carbon ion beam (290MeV / u, 6cm SOBP center). From the second day, 0.2 ml of the combination of eMIP (10μg / ml) and HSP70 (2.5μg / ml) or 0.2 ml of the combination of eMIP (10μg / ml) and HSP60 (2.5μg / ml) was administered once a day through the tail vein for 5 consecutive days. The mice in each group, including the group implanted with cancer cells only (control), the group irradiated with 3 Gy carbon ion beam only (C3Gy), the group given eMIP and HSP60 after irradiation (C3Gy+eMIP+HSP60), and the group given eMIP and HSP70 after irradiation (C3Gy+eMIP+HSP70), were dissected 21 days after irradiation, and the left (1st lobe) and right (4th lobe) lungs were removed, and the number of metastatic cancer spots in the lungs was counted after staining with Bouin's solution.
[0102] 2) Experimental results
[0103] The results of the test are as follows Figure 4 Compared with the group with only cancer cells transplanted (control), the group with only 3Gy carbon ion beam irradiation (C3Gy) had a significant decrease in the number of lung metastatic cancer spots. The reduction in lung metastatic cancer spots was paralleled by the decrease in tumor volume at the transplant site (refer to Figure 3). The results of the 3Gy carbon ion beam irradiation group were used as a new control group. There was no difference in the number of cancer metastases between this group and the group that was administered with eMIP and HSP60 after irradiation. However, in contrast, no lung metastatic cancer spots were detected in the group that was administered with eMIP and HSP70 after irradiation, indicating that the anti-cancer metastasis effect of this combination therapy was further enhanced.
[0104] Example 4: After local carbon ion beam irradiation, when two polypeptide compositions of eMIP and HSP70 were administered, the number of lung metastases after administration of different concentrations of HSP70
[0105] 1) Experimental methods
[0106] Mice: Female BALB / c mice were purchased from SLC, Japan, at 6 weeks of age and were used at 7 weeks of age after cis-rearing.
[0107] Drugs: eMIP of sequence A and three peptides of HSP60 and HSP70
[0108] Cancer cells: Mouse colon cancer Colon26
[0109] Method 1×10 5 Colon26 cells were implanted subcutaneously in the hind limbs. After 9 days, when the diameter of the transplanted tumor reached about 1.0 cm, the tumor size was uniformly grouped and irradiated with 3Gy carbon ion beam (290MeV / u, 6cm SOBP center). From the second day, 0.2 ml of the combination of eMIP (10μg / ml) and HSP70 (10μg / ml), or 0.2 ml of the combination of eMIP (10μg / ml) and HSP70 (2.5μg / ml), or 0.2 ml of the combination of eMIP (10μg / ml) and HSP70 (0.625μg / ml) were administered once a day through the tail vein for 5 consecutive days. After 21 days of radiation irradiation, the mice in each group were dissected, and the left (1st lobe) and right (4th lobe) lungs were removed. The number of metastatic cancer spots in the lungs was counted after staining with Bouin's solution.
[0110] 2) Experimental results
[0111] The results of the test are as follows Figure 5 As shown. Figure 4 Similarly, in this experiment, no lung cancer metastasis was observed in the group that received 3Gy carbon ion beam irradiation and then intravenously administered eMIP2 (2μg) and HSP70 (0.5μg) for five consecutive days. However, no metastasis inhibition effect was found in the group that received 2μg or 0.125μg of HSP70 daily after irradiation compared to the irradiation alone group.
Claims
1. A heavy ion beam therapy composition, include: The first reagent combination, wherein the first reagent combination includes a chemokine and an alarmin.
2. The heavy ion beam therapy composition according to claim 1, It is characterized in that The composition further includes a first member capable of generating a heavy ion beam.
3. The heavy ion beam therapy composition according to claim 2, It is characterized in that The heavy ion beam is a carbon ion beam.
4. The heavy ion beam therapy composition according to any one of claims 1 to 3, It is characterized in that The chemokine is CCL3, a variant of CCL3, a fragment of CCL3 or a derivative of CCL3.
5. The heavy ion beam therapy composition according to any one of claims 1 to 3, It is characterized in that The chemokine has an amino acid sequence in which the first alanine of CCL3 is deleted and the 27th aspartic acid is substituted by alanine.
6. The heavy ion beam therapy composition according to any one of claims 1 to 5, It is characterized in that The alarmin is a heat shock protein.
7. The heavy ion beam therapy composition according to any one of claims 6, It is characterized in that The heat shock protein is HSP70.
8. Use of the composition according to any one of claims 1 to 7 for preparing a kit for treating cancer.
9. The use according to claim 8, It is characterized in that The cancer is a solid cancer.
10. A cancer treatment kit, include: The composition according to any one of claims 1 to 7.
